Advertisement

γc cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1

Published:August 31, 2022DOI:https://doi.org/10.1016/j.jcyt.2022.07.012

      Abstract

      Background aims

      The stimulatory natural killer–dendritic cell axis in the tumor microenvironment could play a critical role in stimulating cytotoxic T cells and driving immune responses against cancer.

      Methods

      We established a novel treatment protocol by adroitly combining chemotherapy with doxorubicin and immunotherapy with dendritic cells and natural killer cells against a highly aggressive and malignant lymphoma called Dalton's lymphoma.

      Results

      Our data suggest that binary application of adoptive cell therapy and chemotherapy nearly cures (95%) early-stage experimental lymphoma. In the case of mid-stage cancer, the success rate was significantly lower but still impressive (75%). Our results demonstrated that the application of combination therapy in early-stage cancer significantly reduced the tumor volume and extended the lifespan of the experimental animal in addition to reinvigorating the immune system, including restoring the effector functions of dendritic cells and natural killer cells. The novel protocol limits the metastasis of tumor cells in vascularized organs and rearms the adaptive immune response mediated by dendritic cells and CD4+ and CD8+ T cells.

      Conclusions

      Combination therapy in the early stage alters the cytokine profile, increases interferon-γ and tumor necrosis factor-α in the serum of treated animals and downregulates programmed cell death protein 1 expression in CD8+ T cells. Thus, cooperative and cognitive interactions between dendritic cells and natural killer cells in addition to therapy with doxorubicin promote the immune response and tumoricidal activities against lymphoma.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Banchereau J
        • Briere F
        • Caux C
        • Davoust J
        • Lebecque S
        • Liu YJ
        • et al.
        Immunobiology of dendritic cells.
        Annu Rev Immunol. 2000; 18: 767-811https://doi.org/10.1146/annurev.immunol.18.1.767
        • Rescigno M
        • Borrow P.
        The host-pathogen interaction: new themes from dendritic cell biology.
        Cell. 2001; 106: 267-270https://doi.org/10.1016/s0092-8674(01)00454-8
        • Kokhaei P
        • Choudhury A
        • Mahdian R
        • Lundin J
        • Moshfegh A
        • Osterborg A
        • et al.
        Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.
        Leukemia. 2004; 18: 1810-1815https://doi.org/10.1038/sj.leu.2403517
        • Altfeld M
        • Fadda L
        • Frleta D
        • Bhardwaj N.
        DCs and NK cells: critical effectors in the immune response to HIV-1.
        Nat Rev Immunol. 2011; 11: 176-186https://doi.org/10.1038/nri2935
        • Gerosa F
        • Baldani-Guerra B
        • Nisii C
        • Marchesini V
        • Carra G
        • Trinchieri G.
        Reciprocal activating interaction between natural killer cells and dendritic cells.
        J Exp Med. 2002; 195: 327-333https://doi.org/10.1084/jem.20010938
        • Broz M
        • Binnewies M
        • Boldajipour B
        • Nelson A
        • Pollock J
        • Erle D
        • et al.
        Dissecting the tumor myeloid compartment reveals rare activating antigen presenting cells, critical for T cell immunity.
        Cancer Cell. 2014; 26: 638-652https://doi.org/10.1016/j.ccell.2014.09.007
        • Salmon H
        • Idoyaga J
        • Rahman A
        • Leboeuf M
        • Remark R
        • Jordan S
        • et al.
        Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition.
        Immunity. 2016; 44: 924-938https://doi.org/10.1016/j.immuni.2016.03.012
        • Sánchez-Paulete AR
        • Cueto FJ
        • Martínez-López M
        • Labiano S
        • Morales-Kastresana A
        • Rodríguez-Ruiz ME
        • et al.
        Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells.
        Cancer Discov. 2016; 6: 71-79https://doi.org/10.1158/2159-8290.CD-15-0510
        • Hildner K
        • Edelson BT
        • Purtha WE
        • Diamond M
        • Matsushita H
        • Kohyama M
        • et al.
        Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.
        Science. 2008; 322: 1097-1100https://doi.org/10.1126/science.1164206
        • Spranger S
        • Dai D
        • Horton B
        • Gajewski TF.
        Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy.
        Cancer Cell. 2017; 31 (.e4): 711-723https://doi.org/10.1016/j.ccell.2017.04.003
        • Böttcher JP
        • Bonavita E
        • Chakravarty P
        • Blees H
        • Cabeza-Cabrerizo M
        • Sammicheli S
        • et al.
        NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control.
        Cell. 2018; 172 (.e14): 1022-1037https://doi.org/10.1016/j.cell.2018.01.004
        • Topalian SL
        • Drake CG
        • Pardoll DM.
        Immune checkpoint blockade: a common denominator approach to cancer therapy.
        Cancer Cell. 2015; 27: 450-461https://doi.org/10.1016/j.ccell.2015.03.001
        • Rizvi NA
        • Hellmann MD
        • Snyder A
        • Kvistborg P
        • Makarov V
        • Havel JJ
        • et al.
        Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer.
        Science. 2015; 348: 124-128https://doi.org/10.1126/science.aaa1348
        • Moretta A
        • Bottino C
        • Mingari MC
        • Biassoni R
        • Moretta L.
        What is a natural killer cell?.
        Nat Immunol. 2002; 3: 6-8https://doi.org/10.1038/ni0102-6
        • Langers I
        • Renoux VM
        • Thiry M
        • Delvenne P
        • Jacobs N.
        Natural killer cells: role in local tumor growth and metastasis.
        Biologics. 2012; 6: 73-82https://doi.org/10.2147/BTT.S23976
        • Waldmann TA
        • Tagaya Y.
        The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.
        Annu Rev Immunol. 1999; 17: 19-49https://doi.org/10.1146/annurev.immunol.17.1.19
        • Ogasawara K
        • Hida S
        • Azimi N
        • Tagaya Y
        • Sato T
        • Yokochi-Fukuda T
        • et al.
        Requirement for IRF-1 in the microenvironment supporting development of natural killer cells.
        Nature. 1998; 391: 700-703https://doi.org/10.1038/35636
        • Ohteki T
        • Yoshida H
        • Matsuyama T
        • Duncan GS
        • Mak TW
        • Ohashi PS.
        The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells.
        J Exp Med. 1998; 187: 967-972https://doi.org/10.1084/jem.187.6.967
        • Kennedy MK
        • Glaccum M
        • Brown SN
        • Butz EA
        • Viney JL
        • Embers M
        • et al.
        Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.
        J Exp Med. 2000; 191: 771-780https://doi.org/10.1084/jem.191.5.771
        • Lodolce JP
        • Boone DL
        • Chai S
        • Swain RE
        • Dassopoulos T
        • Trettin S
        • et al.
        IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.
        Immunity. 1998; 9: 669-676https://doi.org/10.1016/s1074-7613(00)80664-0
        • Ohteki T
        • Suzue K
        • Maki C
        • Ota T
        • Koyasu S
        Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response.
        Nat Immunol. 2001; 2: 1138-1143https://doi.org/10.1038/ni729
        • Kuwajima S
        • Sato T
        • Ishida K
        • Tada H
        • Tezuka H
        • Ohteki T
        Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation.
        Nat Immunol. 2006; 7: 740-746https://doi.org/10.1038/ni1348
        • Hira SK
        • Mondal I
        • Bhattacharya D
        • Manna PP
        Downregulation of endogenous STAT3 augments tumoricidal activity of interleukin 15 activated dendritic cell against lymphoma and leukemia via TRAIL.
        Exp Cell Res. 2014; 327: 192-208https://doi.org/10.1016/j.yexcr.2014.08.012
        • Hira SK
        • Mondal I
        • Bhattacharya D
        • Gupta KK
        • Manna PP
        Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-α.
        Int J Biochem Cell Biol. 2015; 67: 1-13https://doi.org/10.1016/j.biocel.2015.08.002
        • Hira SK
        • Mondal I
        • Manna PP
        Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma.
        Cytotherapy. 2015; 17: 647-664https://doi.org/10.1016/j.jcyt.2015.01.006
        • Gupta U
        • Hira SK
        • Singh R
        • Paladhi A
        • Srivastava P
        • Pratim Manna P
        Essential role of TNF-α in gamma c cytokine aided crosstalk between dendritic cells and natural killer cells in experimental murine lymphoma.
        Int Immunopharmacol. 2020; 78106031https://doi.org/10.1016/j.intimp.2019.106031
        • Hira SK
        • Rej A
        • Paladhi A
        • Singh R
        • Saha J
        • Mondal I
        • et al.
        Galunisertib drives Treg fragility and promotes dendritic cell-mediated immunity against experimental lymphoma.
        IScience. 2020; 23101623https://doi.org/10.1016/j.isci.2020.101623
        • Zitvogel L.
        Dendritic and natural killer cells cooperate in the control/switch of innate immunity.
        J Exp Med. 2002; 195 (F9-14)https://doi.org/10.1084/jem.20012040
        • Fernandez NC
        • Lozier A
        • Flament C
        • Ricciardi-Castagnoli P
        • Bellet D
        • Suter M
        • et al.
        Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.
        Nat Med. 1999; 5: 405-411https://doi.org/10.1038/7403
        • Gasser S
        • Raulet D.
        The DNA damage response, immunity and cancer.
        Semin Cancer Biol. 2006; 16: 344-347https://doi.org/10.1016/j.semcancer.2006.07.004
        • van den Broeke LT
        • Daschbach E
        • Thomas EK
        • Andringa G
        • Berzofsky JA.
        Dendritic cell-induced activation of adaptive and innate antitumor immunity.
        J Immunol. 2003; 171: 5842-5852https://doi.org/10.4049/jimmunol.171.11.5842
        • Karimi K
        • Boudreau JE
        • Fraser K
        • Liu H
        • Delanghe J
        • Gauldie J
        • et al.
        Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.
        Mol Ther. 2008; 16: 411-418https://doi.org/10.1038/sj.mt.6300347
        • Degli-Esposti MA
        • Smyth MJ.
        Close encounters of different kinds: dendritic cells and NK cells take centre stage.
        Nat Rev Immunol. 2005; 5: 112-124https://doi.org/10.1038/nri1549
        • Boudreau JE
        • Bridle BW
        • Stephenson KB
        • Jenkins KM
        • Brunellière J
        • Bramson JL
        • et al.
        Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.
        Mol Ther. 2009; 17: 1465-1472https://doi.org/10.1038/mt.2009.95
        • Goding SR
        • Yu S
        • Bailey LM
        • Lotze MT
        • Basse PH.
        Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
        Clin Immunol. 2017; 177: 76-86https://doi.org/10.1016/j.clim.2016.06.013
        • Blake SJ
        • Stannard K
        • Liu J
        • Allen S
        • Yong MCR
        • Mittal D
        • et al.
        Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy.
        Cancer Discov. 2016; 6: 446-459https://doi.org/10.1158/2159-8290.CD-15-0944
        • Dougall WC
        • Kurtulus S
        • Smyth MJ
        • Anderson AC.
        TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
        Immunol Rev. 2017; 276: 112-120https://doi.org/10.1111/imr.12518
        • Piccioli D
        • Sbrana S
        • Melandri E
        • Valiante NM.
        Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells.
        J Exp Med. 2002; 195: 335-341https://doi.org/10.1084/jem.20010934
        • Ferlazzo G
        • Tsang ML
        • Moretta L
        • Melioli G
        • Steinman RM
        • Münz C.
        Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.
        J Exp Med. 2002; 195: 343-351https://doi.org/10.1084/jem.20011149
        • Barry KC
        • Hsu J
        • Broz ML
        • Cueto FJ
        • Binnewies M
        • Combes AJ
        • et al.
        A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
        Nat Med. 2018; 24: 1178-1191https://doi.org/10.1038/s41591-018-0085-8
        • Morandi B
        • Mortara L
        • Chiossone L
        • Accolla RS
        • Mingari MC
        • Moretta L
        • et al.
        Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response.
        PLoS One. 2012; 7: e39170https://doi.org/10.1371/journal.pone.0039170
        • Van Elssen CHMJ
        • Vanderlocht J
        • Oth T
        • Senden-Gijsbers BLMG
        • Germeraad WTV
        • Bos GMJ.
        Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation.
        Blood. 2011; 118: 2473-2482https://doi.org/10.1182/blood-2010-09-307835
        • Martín-Fontecha A
        • Thomsen LL
        • Brett S
        • Gerard C
        • Lipp M
        • Lanzavecchia A
        • et al.
        Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.
        Nat Immunol. 2004; 5: 1260-1265https://doi.org/10.1038/ni1138
        • Mocikat R
        • Braumüller H
        • Gumy A
        • Egeter O
        • Ziegler H
        • Reusch U
        • et al.
        Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses.
        Immunity. 2003; 19: 561-569https://doi.org/10.1016/s1074-7613(03)00264-4
        • Morandi B
        • Mortara L
        • Carrega P
        • Cantoni C
        • Costa G
        • Accolla RS
        • et al.
        NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs.
        Int Immunol. 2009; 21: 599-606https://doi.org/10.1093/intimm/dxp029
        • Balza E
        • Zanellato S
        • Poggi A
        • Reverberi D
        • Rubartelli A
        • Mortara L.
        The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.
        Eur J Immunol. 2017; 47: 743-753https://doi.org/10.1002/eji.201646544